Who Is a Good Candidate for Exosome Therapy?

There is no self-test that determines exosome therapy candidacy — it is decided case by case, after a licensed physician reviews your medical history and goals. In general, the adults discussed as potential candidates in the current literature are those without active cancer, uncontrolled infection, or pregnancy who are exploring non-surgical, physician-guided options for joint discomfort or aesthetic skin and hair concerns (Dimik et al., 2023). Because no exosome product carries FDA approval, every use remains investigational, and a physician — not the product itself — makes the candidacy call (U.S. Food and Drug Administration [FDA], n.d.).

What This Means

Exosomes are tiny, membrane-bound particles that cells release naturally. They carry proteins, lipids, and genetic material that cells use to communicate with one another, and in regenerative medicine, exosomes are typically derived from mesenchymal stem cells and studied for a possible role in tissue-repair signaling (Lee et al., 2024).

As of 2026, the FDA has not approved any exosome product for any use in humans (FDA, n.d.). That means exosome therapy is offered as an investigational option, not an FDA-cleared product with a defined, guaranteed function. This article can describe what exosome therapy is being studied for — it cannot promise a specific outcome for any individual.

Candidacy

Candidacy discussions in the literature and in clinical practice generally center on a few recurring factors.

Joint or soft-tissue discomfort. Adults who have not found adequate relief from conservative, first-line care sometimes ask about additional, physician-guided options as part of a broader evaluation.

Aesthetic and hair goals. People already considering microneedling, resurfacing, or a hair-restoration consultation sometimes raise exosome-based adjuncts as part of that conversation.

Who is typically excluded. Pregnancy, active or recent cancer, and uncontrolled active infection are the exclusions that come up most consistently. Exosomes function as cellular signaling carriers, and researchers have flagged theoretical concerns about how that signaling could interact with pregnancy physiology or existing cancer biology — reasons for caution rather than settled findings (Dimik et al., 2023).

None of this is a checklist a patient can complete alone. It is a starting point for the conversation a physician has to have with you directly.

Clinical Evaluation

A physician evaluation for exosome therapy candidacy typically includes a review of your medical history and current medications — especially immunosuppressants — a discussion of your specific goals, a review of prior imaging or diagnoses relevant to your concern, and a plain conversation about the investigational status of exosome products, including what is and is not known. Informed consent covering that status is part of the process, not an afterthought.

Available Options

Exosome therapy is one option among several, and a thorough evaluation should cover the alternatives, not just the newest one. For joint and musculoskeletal concerns, conventional options include physical therapy, NSAIDs, corticosteroid injections, platelet-rich plasma (PRP), and, when indicated, surgical referral. For hair thinning, FDA-approved options such as topical minoxidil and prescription finasteride have a longer track record. For skin concerns, dermatologist-directed options include retinoids, chemical peels, and laser resurfacing. Exosome-based options sit alongside these as an investigational, physician-guided addition, not a replacement for a full discussion of what is already established.

Benefits, Limitations and Risks

Proposed benefits under active study include cell-free delivery — no live cells are transplanted — and a signaling role in supporting tissue-repair processes (Lee et al., 2024). These remain proposed and studied, not proven or guaranteed outcomes for any individual.

Limitations are significant. There is no FDA-approved exosome product, no standardized manufacturing process across providers, and wide variability in exosome concentration, purity, and source from one product to another (Lee et al., 2024).

Risks reported to the FDA include infection, allergic or immune reactions, and, in a small number of reported cases, serious adverse events tied to unapproved cell and exosome products (FDA, 2019). Because exosomes are biologically active signaling particles, researchers have also raised theoretical questions about their interaction with existing cancer cells, part of why active or recent cancer is a commonly cited exclusion (Dimik et al., 2023). No outcome, safety profile, or timeline can be promised in advance.

What the Evidence Shows

The evidence base for exosome therapy has grown substantially. Lee et al. (2024) catalog a wide and expanding range of early clinical applications across regenerative medicine, oncology, and diagnostics. What the evidence does establish: exosomes are biologically active, cell-derived particles with a real and growing research program behind them, including early-phase human studies in several specialties.

What the evidence does not yet establish: large, randomized, controlled trials proving safety and effectiveness for most aesthetic or musculoskeletal indications; standardized dosing, purity, or manufacturing across providers; long-term outcome or safety data; or that any individual patient will experience a particular result. Reviewers of the field are explicit that research here is still at a relatively early stage (Lee et al., 2024; Mayo Clinic Press, n.d.).

Recovery / Next Steps

If a physician evaluation identifies you as a reasonable candidate for further discussion, the next step is typically a more detailed conversation about the specific protocol being considered, a written informed-consent process that plainly states the investigational status, and a follow-up plan so your physician can track how you respond. There is no fixed recovery period to describe in general terms — what happens next depends entirely on the specific procedure and the findings of your evaluation.

Orlando Considerations

Florida’s 2025 stem cell law (Fla. Stat. § 458.3245, 2025) created a specific legal framework letting physicians use certain FDA-unapproved stem cell products for orthopedic, pain, and wound-care purposes, under defined sourcing and consent requirements. That law does not extend to exosomes: it excludes ancillary products used in the manufacture of human cells, which is understood to exclude exosome and secretome products from its coverage. In practical terms, exosome therapy offered in Orlando, or anywhere else in Florida, is governed by the FDA’s general framework for investigational biologics, not by the state’s newer stem cell statute. That is a meaningful distinction if you are comparing providers or asking how a given offering is regulated.

Frequently Asked Questions

Is exosome therapy FDA-approved?

No. As of 2026, no exosome product has received FDA approval for any use. It is offered as an investigational option after a physician evaluation, not as an approved product with a guaranteed outcome (FDA, n.d.).

Can someone with a cancer history be a candidate?

Active or recent cancer is one of the most consistently cited exclusions in the literature, due to theoretical concerns about how exosome signaling could interact with existing cancer biology. Anyone with a cancer history should raise it directly with the evaluating physician (Dimik et al., 2023).

Is exosome therapy the same as stem cell therapy?

No. Exosomes are cell-free particles released by cells; stem cell therapy involves live cells. They are related areas of regenerative medicine research but are studied and regulated separately (Lee et al., 2024).

How long does a candidacy evaluation take?

It varies by provider and by how much history and prior imaging need review. The evaluation itself, covering history, goals, and a conversation about investigational status, is what determines candidacy, not a fixed timeline.

What disqualifies someone from exosome therapy?

Pregnancy, active or recent cancer, and uncontrolled active infection are the most commonly cited exclusions. A physician evaluation is the only way to know how these apply to your specific situation.

References

This article is for general education and does not constitute medical advice or a promise of any specific outcome. Exosome products are investigational, have not been approved by the FDA for any use, and are not FDA-approved to diagnose, cure, mitigate, treat, or prevent any disease. Individual circumstances vary, and candidacy and care options are determined only after a medical evaluation by a licensed physician.

Medically reviewed by Kenny Chantasi, DO.

Dimik, M., Abeysinghe, P., Logan, J., & Mitchell, M. (2023). The exosome: A review of current therapeutic roles and capabilities in human reproduction. Drug Delivery and Translational Research, 13(2), 473–502. https://doi.org/10.1007/s13346-022-01225-3

Florida Statutes § 458.3245 (2025). Stem cell therapy. The Florida Senate. https://www.flsenate.gov/Laws/Statutes/2025/458.3245

Lee, K. W. A., Chan, L. K. W., Hung, L. C., Phoebe, L. K. W., Park, Y., & Yi, K.-H. (2024). Clinical applications of exosomes: A critical review. International Journal of Molecular Sciences, 25(14), 7794. https://doi.org/10.3390/ijms25147794

Mayo Clinic Press. (n.d.). Beyond stem cells, regenerative medicine finds exosomes. https://mcpress.mayoclinic.org/research-innovation/beyond-stem-cells-regenerative-medicine-finds-exosomes/

U.S. Food and Drug Administration. (n.d.). Consumer alert on regenerative medicine products including stem cells and exosomes. https://www.fda.gov/vaccines-blood-biologics/consumers-biologics/consumer-alert-regenerative-medicine-products-including-stem-cells-and-exosomes

U.S. Food and Drug Administration. (2019, December 6). Public safety notification: Exosome products. https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/public-safety-notification-exosome-products

Last medically reviewed: September 22, 2026

Related reading

• What Are the Risks of Exosome Therapy?
• Can Exosome Therapy Help With Hair Loss?
• How Much Does Exosome Therapy Cost?
• Is Exosome Therapy FDA-Approved?

More questions answered on the PrimeCell patient blog, or see frequently asked questions.

Related services at PrimeCell

PrimeCell is a physician-led practice in Orlando. Candidacy for any procedure is determined at an in-person evaluation.